ICU Medical Inc (ICUI)

Otsuka ICU Medical has commenced construction on a 500,000-square-foot expansion of its North Austin campus, a $500 million project expected to double the existing facility's size by 2030. This expansion aims to enhance the reliability and resilience of the U.S. IV products supply chain, a critical need highlighted by past shortages. The joint venture plans further life sciences investment in the Austin area and seeks to strengthen its manufacturing footprint, expand non-DEHP capabilities, and introduce innovation.

The average ICU Medical DevOps in Logan, UT earns an estimated $122,305 annually, including a base salary of $108,003 and a $14,303 bonus, which is higher than the US average for DevOps. Salaries can range from $46,880 to $275,000, and the Engineering Department at ICU Medical earns more than the Marketing Department. Most DevOps employees at ICU Medical feel they are not fairly compensated, but the majority are satisfied with their benefits.

Madison Asset Management LLC has acquired a new position in ICU Medical, Inc. (NASDAQ:ICUI), purchasing 18,088 shares valued at approximately $2.65 million. This comes as institutional investors collectively own 96.1% of the company. Analysts maintain a positive outlook with a "Moderate Buy" rating and an average price target of $192.80, while the company recently surpassed earnings expectations but saw significant insider selling.

The average ICU Medical HR Specialist in Auburn, AL earns an estimated $75,330 annually, which is slightly higher than the US average for this role. The HR Department at ICU Medical in Auburn, AL, also earns more on average than the IT Department. Most HR Specialists at ICU Medical believe their compensation is not fair, but a majority are satisfied with their benefits.

ICU Medical (ICUI) reported softer Q2 2026 earnings but saw a significant increase in six-month net income and raised its full-year 2026 GAAP net income and EPS guidance. This upgraded guidance suggests improving profitability and operational efficiencies, despite ongoing challenges related to product recalls and integration costs. The company's investment narrative centers on its role as a core provider of infusion systems, with a long-term forecast of $2.5 billion revenue and $173.2 million earnings by 2029, and a fair value estimate of $191.50 per share.